Bioventus Inc. Financials
Bioventus Inc. (BVS) reported $581.8M in revenue over the twelve months to Jun 27, 2026, up 3.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Bioventus’s dominant mechanic is a margin-led turnaround: nearly flat sales now produce materially more profit and cash.
The earnings-quality shift is clear: FY2025 operating cash flow of$74.7M was more than three times net income of$22.7M . With free cash flow nearly matching operating cash flow, the turnaround reflects cash conversion rather than profit alone.
Revenue held near
The balance-sheet posture improved alongside profitability: long-term debt fell to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bioventus Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bioventus Inc. has an operating margin of 9.5%, meaning the company retains $10 of operating profit per $100 of revenue. This results in a moderate score of 34/100, indicating healthy but not exceptional operating efficiency. This is up from -2.6% the prior year.
Bioventus Inc.'s revenue declined 0.9% year-over-year, from $573.3M to $568.1M. This contraction results in a growth score of 52/100.
Bioventus Inc. has elevated debt relative to equity (D/E of 1.52), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 28/100, reflecting increased financial risk.
Bioventus Inc.'s current ratio of 1.70 indicates adequate short-term liquidity, earning a score of 49/100. The company can meet its near-term obligations, though with limited headroom.
Bioventus Inc. has a free cash flow margin of 12.7%, earning a moderate score of 63/100. The company generates positive cash flow after capital investments, but with room for improvement.
Bioventus Inc.'s ROE of 12.3% shows moderate profitability relative to equity, earning a score of 33/100. This is up from -24.4% the prior year.
Bioventus Inc. scores 1.85, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($945.3M) relative to total liabilities ($455.1M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bioventus Inc. passes 8 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Bioventus Inc. generates $3.28 in operating cash flow ($74.7M OCF vs $22.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Bioventus Inc. generated $568.1M in revenue in fiscal year 2025. This represents a decrease of 0.9% from the prior year.
Bioventus Inc.'s EBITDA was $101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 193.9% from the prior year.
Bioventus Inc. reported $22.7M in net income in fiscal year 2025. This represents an increase of 162.9% from the prior year.
Bioventus Inc. earned $0.33 per diluted share (EPS) in fiscal year 2025. This represents an increase of 158.9% from the prior year.
Cash & Balance Sheet
Bioventus Inc. generated $72.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 90.8% from the prior year.
Bioventus Inc. held $51.2M in cash against $279.0M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Bioventus Inc.'s gross margin was 68.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.
Bioventus Inc.'s operating margin was 9.5% in fiscal year 2025, reflecting core business profitability. This is up 12.2 percentage points from the prior year.
Bioventus Inc.'s net profit margin was 4.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 10.3 percentage points from the prior year.
Bioventus Inc.'s ROE was 12.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 36.8 percentage points from the prior year.
Capital Allocation
Bioventus Inc. invested $12.1M in research and development in fiscal year 2025. This represents a decrease of 13.2% from the prior year.
Bioventus Inc. invested $2.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 154.7% from the prior year.
Not reported for fiscal year 2025.
BVS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $153.2M+16.0% | $132.1M-16.3% | $157.9M+13.9% | $138.7M-6.1% | $147.7M+19.2% | $123.9M-19.4% | $153.6M+10.6% | $139.0M |
| Cost of Revenue | $47.5M+15.1% | $41.3M-15.9% | $49.1M+10.6% | $44.4M-2.5% | $45.6M+11.6% | $40.8M-19.9% | $51.0M+12.3% | $45.4M |
| Gross Profit | $105.7M+16.4% | $90.8M-16.6% | $108.8M+15.4% | $94.2M-7.7% | $102.1M+22.9% | $83.1M-19.1% | $102.7M+9.7% | $93.6M |
| R&D Expenses | $3.2M+28.6% | $2.5M-18.0% | $3.0M+2.9% | $2.9M-7.8% | $3.2M+5.3% | $3.0M-7.9% | $3.3M-14.9% | $3.8M |
| SG&A Expenses | $82.7M+5.6% | $78.3M-5.4% | $82.8M+5.2% | $78.7M-0.6% | $79.1M+7.6% | $73.5M-15.4% | $86.9M+6.6% | $81.5M |
| Operating Income | $19.1M+127.3% | $8.4M-56.8% | $19.5M+73.2% | $11.3M-38.7% | $18.4M+277.2% | $4.9M-36.8% | $7.7M+111.2% | $3.6M |
| Income Tax | -$20.9M-3759.7% | $571K+118.0% | -$3.2M-578.2% | $664K-36.2% | $1.0M+1195.8% | -$95K-117.3% | $550K-6.6% | $589K |
| Net Income | $33.4M+974.2% | $3.1M-78.9% | $14.8M+367.7% | $3.2M-57.7% | $7.5M+382.9% | -$2.6M-579.6% | -$388K+92.5% | -$5.2M |
| EPS (Diluted) | $0.47+1075.0% | $0.04-81.0% | $0.21+320.0% | $0.05-54.5% | $0.11+375.0% | -$0.04 | $0.00+100.0% | -$0.08 |
Not reported in any period shown, so not listed: Interest Expense.
BVS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $673.3M+3.5% | $650.5M-4.8% | $683.6M-2.6% | $701.6M-0.7% | $706.8M+2.2% | $691.4M-5.0% | $728.0M-5.4% | $769.5M |
| Current Assets | $257.5M+3.1% | $249.8M-8.4% | $272.8M-2.9% | $280.9M+2.1% | $275.2M+10.4% | $249.4M-9.5% | $275.6M-7.7% | $298.7M |
| Cash & Equivalents | $29.5M-17.8% | $35.8M-30.0% | $51.2M+21.5% | $42.2M+28.1% | $32.9M+44.3% | $22.8M-45.2% | $41.6M-3.5% | $43.1M |
| Inventory | $79.8M-4.1% | $83.2M+1.2% | $82.2M-14.6% | $96.3M-0.2% | $96.5M+2.6% | $94.0M+1.7% | $92.5M+2.7% | $90.0M |
| Accounts Receivable | $138.4M+14.8% | $120.5M-6.1% | $128.3M-1.6% | $130.4M-1.5% | $132.4M+12.1% | $118.1M-7.3% | $127.4M+4.5% | $121.9M |
| Goodwill | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M |
| Total Liabilities | $395.9M-4.9% | $416.3M-8.5% | $455.1M-7.9% | $494.3M-2.2% | $505.5M-0.1% | $505.9M-6.7% | $542.4M-6.9% | $582.7M |
| Current Liabilities | $152.5M+2.9% | $148.1M-7.7% | $160.4M-0.8% | $161.8M-12.9% | $185.7M+6.3% | $174.8M-16.9% | $210.4M-0.5% | $211.5M |
| Long-Term Debt | $229.7M-9.3% | $253.3M-9.2% | $279.0M-10.4% | $311.3M+4.5% | $297.9M-3.5% | $308.6M+0.1% | $308.3M-10.6% | $345.0M |
| Total Equity | $228.3M+20.9% | $188.9M+2.6% | $184.1M+10.8% | $166.1M+3.0% | $161.2M+8.8% | $148.1M+0.1% | $147.9M-0.5% | $148.7M |
| Retained Earnings | -$298.4M+10.1% | -$331.8M+0.9% | -$334.9M+4.2% | -$349.7M+0.9% | -$352.8M+2.1% | -$360.3M-0.7% | -$357.7M-0.8% | -$354.9M |
BVS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $19.9M+122.4% | $8.9M-76.5% | $38.0M+26.1% | $30.1M+16.0% | $25.9M+234.2% | -$19.3M-200.0% | $19.3M+87.3% | $10.3M |
| Capital Expenditures | $960K+67.2% | $574K-1.0% | $580K+22.6% | $473K-30.7% | $683K-17.3% | $826K+43.9% | $574K+796.9% | $64K |
| Free Cash Flow | $18.9M+126.2% | $8.4M-77.6% | $37.4M+26.2% | $29.6M+17.3% | $25.3M+225.3% | -$20.2M-207.5% | $18.7M+82.9% | $10.3M |
| Investing Cash Flow | -$2.5M-328.6% | -$574K+1.0% | -$580K-22.6% | -$473K+65.4% | -$1.4M-65.7% | -$826K-103.4% | $24.1M+37762.5% | -$64K |
| Financing Cash Flow | -$23.4M-1.2% | -$23.1M+18.6% | -$28.4M-42.4% | -$20.0M-36.2% | -$14.7M-1648.4% | $947K+102.2% | -$42.9M-11938.4% | $362K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BVS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.0%+0.2pp | 68.7%-0.2pp | 68.9%+0.9pp | 68.0%-1.2pp | 69.1%+2.1pp | 67.0%+0.2pp | 66.8%-0.5pp | 67.3% |
| Operating Margin | 12.5%+6.1pp | 6.4%-6.0pp | 12.3%+4.2pp | 8.1%-4.3pp | 12.4%+8.5pp | 3.9%-1.1pp | 5.0%+2.4pp | 2.6% |
| Net Margin | 21.8%+19.5pp | 2.4%-7.0pp | 9.3%+7.1pp | 2.3%-2.8pp | 5.1%+7.2pp | -2.1%-1.9pp | -0.3%+3.5pp | -3.7% |
| Return on Equity | 14.6%+13.0pp | 1.7%-6.4pp | 8.0%+6.1pp | 1.9%-2.7pp | 4.6%+6.4pp | -1.8%-1.5pp | -0.3%+3.2pp | -3.5% |
| Return on Assets | 5.0%+4.5pp | 0.5%-1.7pp | 2.2%+1.7pp | 0.4%-0.6pp | 1.1%+1.4pp | -0.4%-0.3pp | -0.1%+0.6pp | -0.7% |
| Current Ratio | 1.690.0x | 1.690.0x | 1.700.0x | 1.74+0.3x | 1.48+0.1x | 1.43+0.1x | 1.31-0.1x | 1.41 |
| Debt-to-Equity | 1.01-0.3x | 1.34-0.2x | 1.52-0.4x | 1.870.0x | 1.85-0.2x | 2.080.0x | 2.08-0.2x | 2.32 |
| FCF Margin | 12.3%+6.0pp | 6.3%-17.4pp | 23.7%+2.3pp | 21.4%+4.3pp | 17.1%+33.4pp | -16.3%-28.5pp | 12.2%+4.8pp | 7.4% |
Similar Companies
Where Bioventus Inc. Ranks
Frequently Asked Questions
What is Bioventus Inc.'s annual revenue?
Bioventus Inc. (BVS) reported $568.1M in total revenue for fiscal year 2025. This represents a -0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bioventus Inc.'s revenue growing?
Bioventus Inc. (BVS) revenue declined by 0.9% year-over-year, from $573.3M to $568.1M in fiscal year 2025.
Is Bioventus Inc. profitable?
Yes, Bioventus Inc. (BVS) reported a net income of $22.7M in fiscal year 2025, with a net profit margin of 4.0%.
What is Bioventus Inc.'s EBITDA?
Bioventus Inc. (BVS) had EBITDA of $101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Bioventus Inc. have?
As of fiscal year 2025, Bioventus Inc. (BVS) had $51.2M in cash and equivalents against $279.0M in long-term debt.
What is Bioventus Inc.'s gross margin?
Bioventus Inc. (BVS) had a gross margin of 68.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bioventus Inc.'s operating margin?
Bioventus Inc. (BVS) had an operating margin of 9.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Bioventus Inc.'s net profit margin?
Bioventus Inc. (BVS) had a net profit margin of 4.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bioventus Inc.'s return on equity (ROE)?
Bioventus Inc. (BVS) has a return on equity of 12.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bioventus Inc.'s free cash flow?
Bioventus Inc. (BVS) generated $72.1M in free cash flow during fiscal year 2025. This represents a 90.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bioventus Inc.'s operating cash flow?
Bioventus Inc. (BVS) generated $74.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bioventus Inc.'s total assets?
Bioventus Inc. (BVS) had $683.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bioventus Inc.'s capital expenditures?
Bioventus Inc. (BVS) invested $2.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bioventus Inc. spend on research and development?
Bioventus Inc. (BVS) invested $12.1M in research and development during fiscal year 2025.
What is Bioventus Inc.'s current ratio?
Bioventus Inc. (BVS) had a current ratio of 1.70 as of fiscal year 2025, which is generally considered healthy.
What is Bioventus Inc.'s debt-to-equity ratio?
Bioventus Inc. (BVS) had a debt-to-equity ratio of 1.52 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bioventus Inc.'s return on assets (ROA)?
Bioventus Inc. (BVS) had a return on assets of 3.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bioventus Inc.'s Altman Z-Score?
Bioventus Inc. (BVS) has an Altman Z-Score of 1.85, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bioventus Inc.'s Piotroski F-Score?
Bioventus Inc. (BVS) has a Piotroski F-Score of 8 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bioventus Inc.'s earnings high quality?
Bioventus Inc. (BVS) has an earnings quality ratio of 3.28x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bioventus Inc.?
Bioventus Inc. (BVS) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.